Skip to main content
SpringerLink
Log in

Antinuclear Antibodies and Cardiovascular Drugs

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Antinuclear antibodies (ANA) can be induced by some drugs used in the treatment of cardiovascular disease. The reported frequency with which these antibodies are detected in patients varies widely. This variation results from a number of factors. The sensitivity of the ANA assay is influenced by the selection of substrates, the concentration of antisera and characteristics of the detection systems such as ultraviolet microscopes or electrophoretic apparatus. The incidence of ANA also varies with age and sex of the patient, being more common in older people and in females. Identification of a drug suspected of producing ANA demands a careful evaluation of the data with precisely standardised laboratory procedures and comparison of data with appropriate control groups of untreated and treated patients.

Cardiovascular drugs associated with increased ANA incidence can be considered in two categories:

  1. A)

    A few drugs induce ANA in most patients if therapy is continued for long enough at high enough dosage. Many of these patients develop systemic lupus erythematosus like-syndromes. This group includes procainamide, hydralazine at high doses and practolol

  2. B)

    A further group of drugs produces ANA in 20 to 30% of patients, few if any, of whom develop SLE. Methyldopa and acebutolol are clearly in this category, while there is some evidence that labetalol, guanethidine and hydralazine at low doses may also be implicated.

Some very preliminary evidence suggests those patients on the β-adrenoceptor blocking drugs atenolol, metoprolol and Oxprenolol exhibit a mildly increased incidence of ANA, but there is no evidence to suggest associated SLE.

Only patients who develop ANA while on treatment with category A drugs require careful monitoring for SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alarcon-Segovia, D.: Drug-induced antinuclear antibodies and lupus syndromes. Drugs 12: 69 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Alarcon-Segovia, D. and Fishbein, E.: Patterns of antinuclear antibodies and lupus-activating drugs. Journal of Rheumatology 2: 167 (1975).

    PubMed  CAS  Google Scholar 

  • Anderson, B. and Stillman, M.R.: False-positive FTA-ABS in hydralazine-induced lupus. Journal of the American Medical Association 239: 1392 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Ashford, R.; Staughton, R. and Brighton, W.D.: Cutaneous vasculitis due to acebutolol. Lancet 2: 462 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Bensaid, J.; Aldigier, J-C. and Gualde, Norbert: Systemic lupus erythematosus syndrome induced by pindolol. British Medical Journal 1: 1603 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Blomgren, S.E.; Condemi, J.J.; Bignall, M.C. and Vaughan, J.H.: Antinuclear antibody induced by procaine amide: a prospective study. New England Journal of Medicine 281: 64 (1969).

    Article  PubMed  CAS  Google Scholar 

  • Bolli, P. and Simpson, F.O.: A preliminary clinical trial of prazosin: a new oral antihypertensive agent. New Zealand Medical Journal 79: 969 (1974).

    PubMed  CAS  Google Scholar 

  • Bolli, P.; Waal-Manning, Hendrika, J.; Simpson, F.O. and Ingrid, H.M.: Treatment of hypertension with labestalol. New Zealand Medical Journal 86: 57 (1977).

    Google Scholar 

  • Booth, R.J.; Bullock, J.Y. and Wilson, J.D.: Antinuclear antibodies in patients on acebutolol. British Journal of Clinical Pharmacology. Submitted (1979).

    Google Scholar 

  • Breckenridge, A.; Dollery, C.T.; Worlledge, S.M.; Holblorow, E.J. and Johnson, G.D.: Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet 2: 1265 (1967).

    Article  PubMed  CAS  Google Scholar 

  • Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Prazosin: A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 163 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Labetalol: A review of its pharmacology and therapeutic use in hypertension. Drugs 15: 251 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Bullock, J.Y.; Booth, R.J. and Wilson, J.D.: Tissue antibodies in a healthy New Zealand population. New Zealand Medical Journal 89: 11 (1979).

    PubMed  CAS  Google Scholar 

  • Carstairs, K.C.; Breckenridge, A.; Dollery, C.T. and Worlledge, S.M.: Incidence of positive direct Coombs test in patients on alpha methyldopa. Lancet 2: 133 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Chan, W.: Less common side effects of methyldopa. Medical Journal of Australia 2: 14 (1977).

    PubMed  CAS  Google Scholar 

  • Cleymaet, J.E. and Nakamura, R.M.: Indirect immunofluorescent antinuclear antibody tests: comparison of sensitivity and specificity of different substrates. American Journal of Clinical Pathology 58: 388 (1972).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Calabrese, L.H.; Clough, J.D.; Tarazi, R.C. and Bravo, E.L.: Development of antinuclear antibodies during acebutolol therapy. Clinical Pharmacology and Therapeutics 25: 800 (1979).

    PubMed  Google Scholar 

  • Condemi, J.J.; Moore-Jones, D.; Vaughan, J.H. and Perry, H.M.: Antinuclear antibodies following hydralazine toxicity. New England Journal of Medicine 276: 486 (1967).

    Article  PubMed  CAS  Google Scholar 

  • Davies, D.M. and Beedie, M.A.: Antinuclear antibodies during procaineamide treatment and drug acetylation. British Medical Journal 3: 682 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Dent, R. and Kellaway, G.S.M.: A pilot trial of labetalol (AH5258A). A combined alpha and beta blocker in the treatment of hypertension. New Zealand Medical Journal 86: 213 (1977).

    PubMed  CAS  Google Scholar 

  • de Soyza, N.; Murphy, M.L.; Kane, J.J. and Laddu, A.R.: Long term suppression of ventricular dysrhythmias by oral acebutolol in coronary artery disease. American Journal of Cardiology 43: 430 (1979).

    Google Scholar 

  • Feltkamp, T.E.W.; Dorhout Mees, E.J. and Niwuwenhuis, M.G.: Autoantibodies related to treatment with chlorthalidone and alpha-methyldopa. Acta Medica Scandinavica 187: 219 (1970)

    Article  PubMed  CAS  Google Scholar 

  • Fyhrqvist, F.: Vasodilators in hypertensive renal insufficiency. In press (Excerpta Medica, Amsterdam 1979).

    Google Scholar 

  • Garner, A. and Rani, A.H.S.: Practolol and ocular toxicity. Antibodies in serum and tears. British Journal of Ophthalmology 60. 684 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Gold, E.F.; Ben-Efraim, S.; Faivisewitz, A.; Steiner, Z. and Klajman, A.: Experimental studies on the mechanism of induction of anti-nuclear antibodies by procainamide. Clinical Immunology and Immunopathology 7: 176 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Griesemer, D.A.: Procainamide-induced lupus. Johns Hopkins Medical Journal 138: 289 (1976).

    Google Scholar 

  • Hayes, J.M.; Graham, R.M.; O’Connell, BP.; Muir, M.R.; Speers, E. and Humphrey, T.J.: Experience with prazosin in the treatment of patients with severe hypertension. Medical Journal of Australia 1: 562 (1976).

    PubMed  CAS  Google Scholar 

  • Henningsen, N.C.; Cederberg, A; Hanson, A. and Johansson, B.W.: Effects of long-term treatment with procaine amide. Acta Medica Scandinavica 198: 475 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Hooper, B.; Whittingham, S.; Mathews, J.D.; Mackay, I.R. and Curnow, D.H.: Autoimmunity in a rural community. Clinical and Experimental Immunology 12: 79 (1972).

    PubMed  CAS  Google Scholar 

  • Karlsson, E.: Clinical pharmacokinetics of procainamide. Clinical Pharmacokinetics 3: 97 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Klajman, A.; Farkas, R.; Gold, E. and Ben-Efraim, S.: Procainamide-induced antibodies to nucleoprotein, denatured and native DNA in human subjects. Clinical Immunology and Immunopathology 3: 525 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Kristensen, B.O.: Does prazosin induce formation of antinuclear factor? British Medical Journal 1. 621 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Ladd, A.T.: Procainamide-induced lupus erythematosus. New England Journal of Medicine 267: 1357 (1962).

    Article  PubMed  CAS  Google Scholar 

  • Lee, S.L. and Chase, P.H.: Drug-induced systemic lupus erythematosus: A critical review. Seminars in Arthritis and Rheumatism 5: 83 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Lee, S.L.; Rivero, I. and Siegel, M.: Activation of systemic lupus erythematosus by drugs. Archives of Internal Medicine 117: 620 (1966).

    Article  PubMed  CAS  Google Scholar 

  • Levy, M. and David D.: Immune reactions associated with practolol therapy. International Journal of Clinical Pharmacology 16: 479 (1978).

    CAS  Google Scholar 

  • Marshall, A.J.; McGrant, M.E. and Barritt, D.W.: Positive antinuclear factor tests with prazosin. British Medical Journal 1: 165 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Melkild, A. and Gaarder, P.I.: Does prazosin induce formation of antinuclear factor? British Medical Journal 1: 620 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Nairn, R.C.: Fluorescent protein tracing. 4th Ed. Churchill Livingstone, Edinburgh, London p. 125 (1976).

    Google Scholar 

  • Page, J.; Saltvedt, E.; Westlie, L.; Shetelig, A. and Fauchald, P.: Die behandlung der refraktaren hypertonic mit prazosin. Therapiewoche 27: 662 (1977).

    Google Scholar 

  • Perry, H.M.; Tan, E.M.; Carmody, S. and Sakamoto, A.: Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. Journal of Laboratory and Clinical Medicine 76: 114 (1970).

    PubMed  Google Scholar 

  • Perry, H.M.: Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. American Journal of Medicine 54: 58 (1973).

    Article  PubMed  Google Scholar 

  • Perry, H.M.; Chaplin, H; Carmody, S.; Haynes, C. and Frei, C.: Immunologic findings in patients receiving methyldopa: A prospective study. Journal of Laboratory and Clinical Medicine 78: 905 (1971).

    PubMed  Google Scholar 

  • Puppala, A.R. and Steinheber, F.U.: Fulminant hepatic failure associated with methyldopa. American Journal of Gastroenterology 68: 578 (1977).

    PubMed  CAS  Google Scholar 

  • Raftery, E.B.: Cutaneous and ocular reactions to practolol. British Medical Journal 4: 653 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Reinhardt, D.J. and Waldron, J.M.: Lupus erythematosus-like syndrome complicating hydralazine (Apresoline) therapy. Journal of the American Medical Association 155: 1491 (1954).

    Article  PubMed  CAS  Google Scholar 

  • Sherman, J.D.; Love, D.E. and Harrington, J.F.: Anaemia, positive lupus and rheumatoid factors with methyldopa. Archives of Internal Medicine 120: 321 (1967).

    Article  PubMed  CAS  Google Scholar 

  • Strandberg, I.; Boman, G.; Hassler, L. and Sjoqvist, F.: Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Medica Scandinavica 200: 367 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Talseth, T.: Clinical pharmacokinetics of hydrallazine. Clinical Pharmacokinetics 2: 317 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Tse, T.F. and Tsui, J.K.C.: Treatment of hypertension with acebutolol. Philippine Journal of Cardiology 6: 49 (1978).

    Google Scholar 

  • Utsinger, P.D.; Zvaifler, N.J. and Bluestein, H.G.: Hypocomplementemia in procainamide-associated systemic lupus erythematosus. Annals of Internal Medicine 84: 293 (1976).

    PubMed  CAS  Google Scholar 

  • Waal-Manning, H.J.: Problems with practolol. Drugs 10: 336 (1975).

    Article  Google Scholar 

  • Weinstein, J.: Complementemia in hydralazine-associated systemic erythematosus. American Journal of Medicine 65: 553 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Wilson, J.D.; Bullock, J.Y. and Booth, R.J.: Autoantibodies in hypertension. Lancet 2: 996 (1978a).

    Article  PubMed  CAS  Google Scholar 

  • Wilson, J.D.; Bullock, J.Y.; Sutherland, D.C.; Main, C.; O’Brien, K.: Antinuclear antibodies (ANA) in patients on non-practolol beta blockers. British Medical Journal 1: 14 (1978b).

    Article  PubMed  CAS  Google Scholar 

  • Wilson, J.D.; Booth, R.J. and Bullock, J.Y.: Antinuclear factor in patients on prazosin. British Medical Journal 1: 553 (1979a).

    Article  PubMed  CAS  Google Scholar 

  • Wilson, J.D.; Bullock, J.Y. and Booth, R.J.: Influence of prazosin on the development of antinuclear antibodies in hypertensive patients. Clinical Pharmacology and Therapeutics 26: 209 (1979b).

    PubMed  CAS  Google Scholar 

  • Woosley, R.L.; Drayer, D.E.; Reidenberg, M.M.; Nies, A.S.; Carr, D. and Oates, J.A.: Effect of acetylator phenotype on the rate at which procainamide induced antinuclear antibodies and the lupus syndrome. New England Journal of Medicine 298: 1157 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Wright, P.: Untoward effects associated with practolol administration: oculomucocutaneous syndrome. British Medical Journal 1: 595 1975).

    Article  PubMed  CAS  Google Scholar 

  • Yudis, M. and Meehan, J.J.: Quinidine-induced lupus nephritis. Journal of the American Medical Association 235: 2000 (1976).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Auckland, School of Medicine, Auckland 3, New Zealand

    J. D. Wilson

Authors
  1. J. D. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilson, J.D. Antinuclear Antibodies and Cardiovascular Drugs. Drugs 19, 292–305 (1980). https://doi.org/10.2165/00003495-198019040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198019040-00004

Keywords

Search

Navigation